Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)
Shauna O'Brien Dec 08, 2014
Inside the Deal
Cubist focuses on drugs that treat infectious diseases, usually in a hospital setting. According to Cubist, it plans to release four new drugs by 2020. This purchase will allow MRK to continue its strategy to focus on areas including diabetes, acute hospital care, vaccines and oncology.
Mutual Funds to Watch
|PVSAX||Putnam Capital Spectrum||6.16%|
|PYSAX||Putnam Equity Spectrum||2.83%|
|VGHCX||Vanguard Health Care||2.60%|
|VTSMX||Vanguard Total Stock Market Index||1.68%|
|VGHCX||Vanguard Health Care||1.17%|
|VFINX||Vanguard 500 Index||1.07%|
The Bottom Line
Sign up for Advisor Access
Receive email updates about best performers, news, CE accredited webcasts and more.